Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ATP2C1

Gene summary for ATP2C1

Gene summary.

Gene information	Species	Human
	Gene symbol	ATP2C1
	Gene ID	27032
	Gene name	ATPase secretory pathway Ca2+ transporting 1
	Gene Alias	ATP2C1A
	Cytomap	3q22.1
	Gene Type	protein-coding
	GO ID	GO:0000041
	UniProtAcc	P98194

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
27032	ATP2C1	CA_HPV_2	Human	Cervix	CC	4.48e-02	2.63e-01	0.0391
27032	ATP2C1	CCI_1	Human	Cervix	CC	9.64e-04	7.07e-01	0.528
27032	ATP2C1	CCI_2	Human	Cervix	CC	6.77e-10	1.12e+00	0.5249
27032	ATP2C1	CCI_3	Human	Cervix	CC	1.13e-15	1.17e+00	0.516
27032	ATP2C1	Tumor	Human	Cervix	CC	6.97e-09	4.55e-01	0.1241
27032	ATP2C1	sample3	Human	Cervix	CC	7.38e-16	4.77e-01	0.1387
27032	ATP2C1	T3	Human	Cervix	CC	4.87e-12	4.55e-01	0.1389
27032	ATP2C1	HTA11_3410_2000001011	Human	Colorectum	AD	1.78e-06	-4.23e-01	0.0155
27032	ATP2C1	HTA11_3361_2000001011	Human	Colorectum	AD	6.82e-03	-4.50e-01	-0.1207
27032	ATP2C1	HTA11_696_2000001011	Human	Colorectum	AD	1.30e-02	-3.87e-01	-0.1464
27032	ATP2C1	HTA11_866_2000001011	Human	Colorectum	AD	2.42e-02	-3.33e-01	-0.1001
27032	ATP2C1	HTA11_866_3004761011	Human	Colorectum	AD	4.02e-04	-3.91e-01	0.096
27032	ATP2C1	HTA11_10711_2000001011	Human	Colorectum	AD	4.33e-03	-3.74e-01	0.0338
27032	ATP2C1	HTA11_7696_3000711011	Human	Colorectum	AD	8.09e-03	-3.22e-01	0.0674
27032	ATP2C1	HTA11_99999974143_84620	Human	Colorectum	MSS	1.12e-12	-5.16e-01	0.3005
27032	ATP2C1	A015-C-203	Human	Colorectum	FAP	2.36e-17	-3.35e-01	-0.1294
27032	ATP2C1	A015-C-204	Human	Colorectum	FAP	3.63e-04	-2.99e-01	-0.0228
27032	ATP2C1	A014-C-040	Human	Colorectum	FAP	4.08e-02	-3.64e-01	-0.1184
27032	ATP2C1	A002-C-201	Human	Colorectum	FAP	3.31e-08	-2.85e-01	0.0324
27032	ATP2C1	A001-C-119	Human	Colorectum	FAP	5.92e-06	-3.72e-01	-0.1557

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00085446	Cervix	CC	epidermis development	83/2311	324/18723	3.91e-11	8.54e-09	83
GO:190382910	Cervix	CC	positive regulation of cellular protein localization	72/2311	276/18723	3.20e-10	4.46e-08	72
GO:007265910	Cervix	CC	protein localization to plasma membrane	73/2311	284/18723	4.95e-10	6.73e-08	73
GO:19907788	Cervix	CC	protein localization to cell periphery	78/2311	333/18723	1.22e-08	9.73e-07	78
GO:005122210	Cervix	CC	positive regulation of protein transport	72/2311	303/18723	2.36e-08	1.70e-06	72
GO:190495110	Cervix	CC	positive regulation of establishment of protein localization	73/2311	319/18723	9.69e-08	5.25e-06	73
GO:19043779	Cervix	CC	positive regulation of protein localization to cell periphery	24/2311	69/18723	1.21e-06	4.15e-05	24
GO:00315328	Cervix	CC	actin cytoskeleton reorganization	31/2311	107/18723	3.34e-06	8.99e-05	31
GO:19030788	Cervix	CC	positive regulation of protein localization to plasma membrane	21/2311	62/18723	8.91e-06	2.03e-04	21
GO:19054778	Cervix	CC	positive regulation of protein localization to membrane	29/2311	106/18723	2.29e-05	4.01e-04	29
GO:00988767	Cervix	CC	vesicle-mediated transport to the plasma membrane	34/2311	136/18723	3.75e-05	5.91e-04	34
GO:00068927	Cervix	CC	post-Golgi vesicle-mediated transport	28/2311	104/18723	4.31e-05	6.61e-04	28
GO:00431228	Cervix	CC	regulation of I-kappaB kinase/NF-kappaB signaling	53/2311	249/18723	4.50e-05	6.87e-04	53
GO:00901509	Cervix	CC	establishment of protein localization to membrane	54/2311	260/18723	7.67e-05	1.05e-03	54
GO:19030768	Cervix	CC	regulation of protein localization to plasma membrane	27/2311	104/18723	1.15e-04	1.44e-03	27
GO:00072497	Cervix	CC	I-kappaB kinase/NF-kappaB signaling	56/2311	281/18723	1.81e-04	2.12e-03	56
GO:00481938	Cervix	CC	Golgi vesicle transport	58/2311	296/18723	2.24e-04	2.54e-03	58
GO:19043758	Cervix	CC	regulation of protein localization to cell periphery	30/2311	125/18723	2.28e-04	2.56e-03	30
GO:19054758	Cervix	CC	regulation of protein localization to membrane	36/2311	175/18723	1.33e-03	1.05e-02	36
GO:00068936	Cervix	CC	Golgi to plasma membrane transport	16/2311	60/18723	2.00e-03	1.46e-02	16

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ATP2C1

SNV

Missense_Mutation

c.514N>C

p.Glu172Gln

p.E172Q

P98194

protein_coding

tolerated(0.17)

benign(0.037)

TCGA-A1-A0SI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ATP2C1

SNV

Missense_Mutation

c.2170N>A

p.Glu724Lys

p.E724K

P98194

protein_coding

deleterious(0.02)

probably_damaging(0.995)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ATP2C1

SNV

Missense_Mutation

c.359N>C

p.Leu120Pro

p.L120P

P98194

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

ATP2C1

SNV

Missense_Mutation

c.1271G>C

p.Gly424Ala

p.G424A

P98194

protein_coding

tolerated(0.3)

benign(0.406)

TCGA-AR-A24Q-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

ATP2C1

SNV

Missense_Mutation

c.1339N>C

p.Asp447His

p.D447H

P98194

protein_coding

deleterious(0.01)

possibly_damaging(0.81)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

ATP2C1

SNV

Missense_Mutation

rs145949576

c.1994C>T

p.Ser665Leu

p.S665L

P98194

protein_coding

deleterious(0)

possibly_damaging(0.611)

TCGA-EW-A6SA-01

Breast

breast invasive carcinoma

Male

<65

I/II

Unknown

ATP2C1

insertion

Nonsense_Mutation

novel

c.195_196insTAGAATAAT

p.Val65_Ser66insTer

p.V65_S66ins*

P98194

protein_coding

TCGA-A7-A26I-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

ATP2C1

deletion

Frame_Shift_Del

c.685delT

p.Cys229ValfsTer4

p.C229Vfs*4

P98194

protein_coding

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ATP2C1

deletion

Frame_Shift_Del

c.340delN

p.Asn115IlefsTer16

p.N115Ifs*16

P98194

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

ATP2C1

SNV

Missense_Mutation

novel

c.2336C>T

p.Pro779Leu

p.P779L

P98194

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		ENFLURANE	ENFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		ISOFLURANE	ISOFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		SEVOFLURANE	SEVOFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		ISOFLURANE	ISOFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		ENFLURANE	ENFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		SEVOFLURANE	SEVOFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		DESFLURANE	DESFLURANE
27032	ATP2C1	ENZYME, TRANSPORTER, DRUGGABLE GENOME		DESFLURANE	DESFLURANE

Page: 1